The evolving field of kinase inhibitors in thyroid cancer.

The evolving field of kinase inhibitors in thyroid cancer.

Item
http://www.wikidata.org/entity/Q38252863
Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancerFasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition.miR-195 is a key regulator of Raf1 in thyroid cancer.Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience.Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.Kinase-targeted cancer therapies: progress, challenges and future directions.Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib.Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge.
P2860

The evolving field of kinase inhibitors in thyroid cancer.

Item
http://www.wikidata.org/entity/Q38252863
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The evolving field of kinase inhibitors in thyroid cancer.
@en
type
label
The evolving field of kinase inhibitors in thyroid cancer.
@en
prefLabel
The evolving field of kinase inhibitors in thyroid cancer.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
The evolving field of kinase inhibitors in thyroid cancer.
@en
P2093
P304
P31
P356
10.1016/J.CRITREVONC.2014.08.007
P433
P478
P50
P577
P698